🫁 Could Lung or Nasal Coatings Help Prevent Aspergillosis?

As research into new ways of preventing lung infections advances, some patients with aspergillosis are asking whether coating the lungs or airways—with a protective spray, gel, or surfactant—might one day protect them from fungal disease.

Here’s what the science says so far.

🔬 What Is Being Researched?

Scientists are currently studying ways to coat the lungs or nasal passages with a protective substance designed to:

• Trap or neutralise viruses, bacteria, or fungal spores
• Stabilise the lung or airway lining
• Prevent inflammation or infection from taking hold

These coatings may come in the form of:

• Dry powder aerosols (inhaled)
• Drug-free nasal gels or sprays

Importantly, these are being developed as preventative measures, not as treatments for people already ill.

🧪 Current Research: Early-Stage, Not Yet for Aspergillosis

1. Dry Powder Lung Surfactants

• These are based on natural surfactants that coat the lungs and keep the air sacs (alveoli) open.
• Tested in animals (e.g., lambs, rabbits) with good results in preventing respiratory distress or injury.
• Used mostly in neonatal care for premature babies.
• Not yet tested for fungal infections or chronic diseases like aspergillosis.

2. Nasal Gel-Coating Sprays

• These sprays form a temporary coating in the nose and upper airways, shown in mice to block viruses like flu or COVID-19.
• Protective effect may last several hours.
• Still in animal testing—no human trials or approvals yet.
• No evidence yet that they can prevent fungal infections like Aspergillus.

📌 Are These Coatings Available Yet?

No. As of now:

• There are no licensed lung or nasal sprays designed to prevent aspergillosis or other fungal lung infections.
• Most studies are in pre-clinical stages (animal research only).
• It may be several years before any human trials begin.

🛡️ Who Might Receive These Preventatives in the Future?

If future research proves these coatings are safe and effective, likely priority groups would include:

🎯 High-risk populations:

• People with chronic aspergillosis (CPA) or ABPA
• Patients on long-term steroids or immunosuppressants
• Individuals with bronchiectasis, COPD, or cystic fibrosis
• Transplant recipients or those with cancer or immune deficiencies
• Elderly people, especially in care homes
• Healthcare or construction workers exposed to dust, spores, or mould
• Hospitalised or ventilated patients (e.g. risk of CAPA in ICU)

❗ What Aspergillosis Patients Should Know

• These technologies are not available yet and remain in the research phase.
• They are being explored as preventative tools, not as treatment for existing fungal infections.
• There is no evidence yet they can prevent Aspergillus infections—but the research is promising.

✅ What You Can Do Now

Until better preventatives are developed, people with aspergillosis can reduce risk by:

• Avoiding high-risk environments (e.g., compost, renovation dust, decaying vegetation)
• Using prescribed antifungals or steroids correctly
• Supporting immune health (e.g., good nutrition, rest, fibre-rich diet)
• Asking doctors about biologics or ongoing research trials if relevant

📘 Final Word

While the idea of coating the lungs or nose to stop infections sounds futuristic, it’s grounded in real science. For people vulnerable to fungal lung disease, this kind of innovation may one day offer protection—especially for those on immunosuppressive treatments or with fragile lungs.

But for now, the best defence remains personalised treatment, avoidance strategies, and good communication between specialists and GPs. We’ll keep watching this space closely as research develops.